COR-1389 / Corteria Pharmaceuticals - LARVOL DELTA

A new CRF2 agonist COR-1389 enhances muscle and metabolic performance while reducing fat in obese mice (EASD 2026) - "COR-1389 as monotherapy or in combination with semaglutide powerfully reduced fat mass while increasing lean mass, enhancing muscle strength and function, and boosting metabolic health. These results demonstrate its potential as a next-generation, differentiated anti-obesity therapy and support its ongoing evaluation in subjects with obesity."

Preclinical • Metabolic Disorders • Obesity • LEP